Cyclacel’s Sapacitabine Nearly Doubles Expected Survival of Elderly Patients With MDS After Front-Line Therapy Failure

Cyclacel’s Sapacitabine Nearly Doubles Expected Survival of Elderly Patients With MDS After Front-Line Therapy Failure

[at noodls] – BERKELEY HEIGHTS, N.J., Oct. 15, 2012 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), will host a conference call today to discuss updated data … more

View todays social media effects on CYCC

View the latest stocks trending across Twitter. Click to view dashboard

Share this post